1
0
BRISBANE, Australia — In a potential breakthrough for global health, researchers have identified a repurposing strategy for an existing blood disorder medication that could significantly improve survival rates for severe malaria. A clinical trial led by the QIMR Berghofer Medical Research Institute suggests that the drug ruxolitinib, when paired with standard antimalarial therapy, reduces life-threatening inflammation and may actually strengthen the body’s long-term immunity against the parasite.
The study, published recently in Science Translational Medicine, addresses a critical gap in current tropical medicine: while modern drugs are highly effective at killing the malaria parasite, they do little to stop the “cytokine storm”—a violent overreaction of the immune system—that often leads to organ failure and death in severe cases.
The Silent Killer: Why Parasite-Killing Isn’t Enough
Malaria remains one of the world’s most persistent public health crises, claiming more than 600,000 lives annually. Truncal to this tragedy is the fact that three-quarters of these deaths occur in children under the age of five.
The culprit is usually Plasmodium falciparum, a parasite transmitted through the bite of infected mosquitoes. Once in the bloodstream, it multiplies rapidly. While frontline treatments like artemether-lumefantrine are excellent at clearing the parasite, the clinical reality remains grim for those with advanced infections.
“While antimalarial treatments are effective at killing the parasite, they don’t directly address the inflammation that contributes to severe illness and death,” explains Associate Professor Bridget Barber, Head of QIMR Berghofer’s Clinical Malaria Group.
When the immune system detects the parasite, it triggers an “early warning system” known as type 1 interferon signaling. In moderate amounts, this helps; in excess, it causes the systemic inflammation that leads to cerebral malaria and respiratory distress.
The Study: A Controlled Challenge
To test if ruxolitinib—a Janus kinase (JAK) inhibitor typically used to treat bone marrow disorders—could dampen this dangerous response, researchers conducted a human “challenge” study.
The trial involved 20 healthy adult volunteers who had never been exposed to malaria. Under strict medical supervision, participants were deliberately infected with P. falciparum. After eight days:
-
All participants received the standard antimalarial treatment.
-
Eleven participants were also given ruxolitinib.
-
Nine participants served as a control group.
Three months later, the volunteers were re-infected to see how their immune systems would handle a secondary exposure—a critical test for long-term protection.
Key Findings
The results offered a “best-of-both-worlds” scenario for the researchers:
-
Safety First: Ruxolitinib was found to be safe and well-tolerated in the context of a malaria infection.
-
Reduced Inflammation: Those who took the drug showed significantly lower levels of inflammatory markers associated with organ damage.
-
Enhanced Immunity: Surprisingly, by preventing the “exhaustion” of the immune system during the first infection, ruxolitinib appeared to help the body mount a more effective response during the second infection.
Moving Toward Elimination
One of the greatest hurdles in eradicating malaria is the lack of a “perfect” vaccine. Current options offer limited duration and varying efficacy. By modulating the host’s own response, ruxolitinib might bridge the gap.
“By boosting the immune system without causing detrimental inflammation… we may be able to overcome these challenges,” says Professor Christian Engwerda, QIMR Berghofer’s Program Director of Infection and Inflammation.
Expert Perspective
Independent experts cautiously welcome the findings. Dr. Elena Rodriguez, a tropical medicine specialist not involved in the study, notes the significance of the “adjunctive therapy” approach.
“We have spent decades focusing solely on the parasite,” says Dr. Rodriguez. “This study reinforces a shift toward ‘host-directed therapy.’ If we can keep the patient’s body stable while the antimalarials do their work, we save lives that would otherwise be lost to the body’s own defense mechanisms.”
Limitations and the Road Ahead
Despite the promising data, researchers urge caution. This trial was a “proof-of-concept” conducted in a highly controlled environment with healthy, previously unexposed adults.
“It’s important to note that the study was not conducted in malaria-endemic regions,” the authors noted in their report. The immune systems of people living in sub-Saharan Africa or Southeast Asia, who face repeated exposures from birth, may react differently to ruxolitinib than those of the Australian volunteers.
Furthermore, ruxolitinib is currently an expensive medication. For it to be a viable tool in the regions where malaria hits hardest, public health advocates would need to address cost and distribution logistics.
What This Means for the Public
For now, standard prevention remains the priority:
-
Use of insecticide-treated bed nets.
-
Prophylactic medication for travelers.
-
Seeking immediate medical attention for fevers following travel to endemic areas.
While ruxolitinib is not yet ready for bedside use in malaria clinics, this study provides a blueprint for a new generation of “smart” treatments that protect the patient as much as they attack the parasite.
References
Primary Study:
-
Webster, R., et al. (2025). “Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum.” Science Translational Medicine. DOI: 10.1126/scitranslmed.aea2531.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
